VOLU SOL INC
10KSB, EX-27, 2001-01-16
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: VOLU SOL INC, 10KSB, 2001-01-16
Next: PFL ENDEAVOR TARGET ACCOUNT, RW, 2001-01-16



<TABLE> <S> <C>


<ARTICLE>                     5

<S>                                        <C>
<PERIOD-TYPE>                              YEAR
<FISCAL-YEAR-END>                          SEP-30-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                         278,421
<SECURITIES>                                         0
<RECEIVABLES>                                   99,293
<ALLOWANCES>                                    21,188
<INVENTORY>                                     50,890
<CURRENT-ASSETS>                               407,416
<PP&E>                                         401,293
<DEPRECIATION>                                 244,978
<TOTAL-ASSETS>                                 467,003
<CURRENT-LIABILITIES>                          229,719
<BONDS>                                              0
                                0
                                  3,829,112
<COMMON>                                           294
<OTHER-SE>                                  (3,592,122)
<TOTAL-LIABILITY-AND-EQUITY>                   237,284
<SALES>                                        496,211
<TOTAL-REVENUES>                               496,211
<CGS>                                          291,213
<TOTAL-COSTS>                                3,665,832
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                             (3,875,648)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                         (3,875,648)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                (3,875,648)
<EPS-BASIC>                                      (2.85)
<EPS-DILUTED>                                    (2.85)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission